Table 1. Antitumor effects of roneparstat and irinotecan against human A204 rhabdoid sarcoma xenografts.

Drug	Na	Doseb (mg/kg/day)	Schedule	TVI%c (day)	CRd	NEDe
irinotecan	8	50	q4dx4	95 (24)**,##	1/8	0/8
roneparstat	7	60×2	2qdx6/wx4w	80 (24)**,#	0/7	0/7
roneparstat plus irinotecan	8	60×2 50	2qdx6/wx4w q4dx4	100 (24)**	8/8	5/8

^aN, number of treated mice

^bTumor fragments were implanted s.c. in the right flank of nude mice at day 0 and treatments started the day after. Roneparstat, dissolved in sterile saline, was administered s.c. at 10 ml/kg; irinotecan, dissolved in sterile distilled water, was delivered i.v. at 15 ml/kg. Drugs were administered, as indicated, alone or in combination.

^cTVI%, tumor volume inhibition percent = 100 − (mean tumor volume of treated mice / mean tumor volume of control mice × 100) determined on day 24 after tumor implantation.

^dCR, complete regressions, i.e. disappearance of the tumors lasting at least ten days after the end of treatments

^eNED, mice with no evidence of disease at the end of the experiment (day 115).

^**P < 0.001 vs control tumors

^#P < 0.05

^##P < 0.01 vs combination-treated tumors, by Student's t test.